SAN CARLOS, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference in New York at the Grand Hyatt New York Hotel on Tuesday, February 5, 2008 at 1:00 p.m. ET.
The presentation and Q&A session will be accessible via a live audio-only Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 19, 2008.
Nektar Therapeutics is a biopharmaceutical company that develops and
enables differentiated therapeutics with its industry-leading PEGylation
and pulmonary drug development platforms. Nektar PEGylation and pulmonary
technology, expertise, manufacturing capabilities have enabled ten approved
products for partners, which include the world's leading pharmaceutical and
biotechnology companies. Nektar also develops its own products by applying
its PEGylation and pulmonary technology platforms to existing medicines
with the objective to enhance performance, such as improving efficacy,
safety and compliance.
|SOURCE Nektar Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved